M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
The new Senate is once again sharpening its ax to cut pharma's DTC advertising tax deductions, a move now backed by a powerhouse group of Democrats.
Lilly's Lartruvo has been a key launch for its oncology business, but thanks to a phase 3 fail, it plans to stop promoting the drug.
NICE initially told Eli Lilly that its breast cancer drug Verzenio wasn't cost-effective. So Lilly dished up a price break—and it worked.
Spectrum is offloading seven drugs and transferring 40% of its total workforce to Aurobindo in a deal to "laser-focus" on novel cancer drugs.
Adamis' partner Sandoz is launching the prefilled syringe at a 16.5% discount to Mylan’s authorized generic EpiPen and Teva’s generic version.
If you thought Amgen osteoporosis candidate Evenity was down for the count, think again.
When doctors first diagnose Parkinson’s patients, their main focus is motor control. And that gives Acadia, maker of Nuplazid, a big job to do.
Merck's latest additions to the multichannel "It's Tru" campaign for cancer drug Keytruda include two TV ads featuring a real oncologist.
Exelixis nabbed an FDA nod for Cabometyx in second-line liver cancer, where Stivarga, Opdivo and Keytruda are already battling it out.
Acorda has moved its entire salesforce over from Ampyra to new launch Inbrija. But it’s not relying solely on that team to get the ball rolling.
